A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
NCT06717113
Summary
Multiple Myeloma (MM), the second most common hematological malignancy, continues to pose challenges in precise clinical identification. As a potential solution, nuclear medicine immuno-PET imaging has emerged as a promising approach. However, traditional full-length antibody probes suffer from delayed tumor uptake peaks and low target-to-background ratios, limiting their clinical utility. In our study, a peptide or nanobody targeting BCMA was developed by computer-aided designing, which was subsequently radiolabeled with 68Ga to create a novel molecular probe, 68Ga-MM-BC1. This research aims to overcome the diagnostic limitations of MM and may also offer valuable insights for molecular-targeted imaging in other malignant tumors.
Eligibility
Inclusion Criteria: * Suspected multiple myeloma patients scheduled for bone marrow aspiration or tissue biopsy within the past 3 months; able to fully understand and voluntarily participate in the study, with signed informed consent; able to cooperate with the examination. * Diagnosed symptomatic multiple myeloma patients; able to fully understand and voluntarily participate in the study, with signed informed consent; able to cooperate with the examination. Exclusion Criteria: * Pregnant women; individuals unable to understand the examination process or who are unable to cooperate.
Conditions2
Interventions2
Related trials
- 68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients — Peking Union Medical College Hospital
- 68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients — Peking Union Medical College Hospital
- CD147 Targeting Nanobody Probe for PET Imaging in Solid Tumors — Hua Zhu
- CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors — Peking University Cancer Hospital & Institute
- Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73 — First Affiliated Hospital of Fujian Medical University
- Lung Nodule Detection Using Ultra-long FOV PET/CT — University Medical Center Groningen
- Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma — Peking University Cancer Hospital & Institute
- PD-L1 Specific [68Ga]Ga-THP-PDL1-3 Probe for PET Imaging in Solid Tumors — Hua Zhu
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06717113